Rezolute's Ersodetug Shows Promising Glycemic Control in Congenital HI Trials
Event summary
- Rezolute reported Phase 3 sunRIZE study data showing significant glycemic control improvements in congenital hyperinsulinism (HI) patients treated with ersodetug.
- FDA acknowledged trial challenges but encouraged Rezolute to submit comprehensive datasets for independent evaluation.
- Rezolute's cash position declined to $120.3M as of March 31, 2026, from $167.9M in June 2025.
- Phase 3 upLIFT study for tumor HI is ongoing with topline results expected in the second half of 2026.
The big picture
Rezolute's progress with ersodetug underscores the challenges of developing treatments for rare, heterogeneous diseases like congenital HI. The FDA's cautious but constructive feedback reflects broader trends in regulatory scrutiny for novel therapies. With a shrinking cash position, Rezolute's ability to secure additional funding or demonstrate clinical efficacy will be critical for sustaining operations and advancing its pipeline.
What we're watching
- Regulatory Pathway
- Whether FDA's independent evaluation will validate ersodetug's efficacy for congenital HI despite lack of statistical significance in sunRIZE study.
- Trial Execution
- The pace at which the upLIFT study for tumor HI enrolls and delivers topline results in the second half of 2026.
- Financial Runway
- How Rezolute manages its declining cash position while advancing multiple clinical programs.
Related topics